CAR-T & Cell Therapy in China
China has developed significant CAR-T cell therapy infrastructure, with multiple approved products and active clinical programmes at specialist haematology centres. For international patients facing relapsed or refractory blood cancers, a structured expert case review can help clarify whether CAR-T may be a relevant option, what eligibility assessment involves, and how coordination with Chinese centres works in practice.
Key Topics Covered
Articles & Guides
CAR-T Therapy in China: What Foreign Patients Should Know
CAR-T Therapy for Lymphoma: Who Is Eligible and What to Expect
CAR-T Therapy for Multiple Myeloma: Who Is Eligible and What to Expect
How Much Does CAR-T Cost in China for International Patients?
Side Effects of CAR-T Therapy: What Patients Should Know
How to Decide Between CAR-T and Other Cancer Therapy After Relapse
CAR-T Cell Therapy for Solid Tumours: CT041 and the Claudin18.2 Breakthrough
Related Services & Areas
CAR-T & Cell Therapy Coordination Service
Our coordination service for international patients exploring CAR-T in China
Online MDT Second Opinion
Request a structured expert review before any treatment decision
Pediatric Leukemia & Blood Disorders
For families facing pediatric leukemia and complex transplant decisions
Haploidentical Transplant
For patients without a matched donor considering haplo-HSCT
Request a Structured CAR-T Eligibility Review
If you or a family member is facing relapsed or refractory disease and wants to understand whether CAR-T therapy in China may be relevant, a structured second opinion is the appropriate first step.